医疗科技初创公司Quibim斥资5000万美元推进医学影像领域的人工智能分析-动脉网

Medtech Startup Quibim Corrals $50M to Advance AI Analysis in Medical Imaging

MedCity News 等信源发布 2025-01-28 20:03



可切换为仅中文







From L-R: Quibim COO Alberto Valiente, CEO Ángel Alberich-Bayarri, VP Finance & Business Intelligence Javier Sáez. Photo by Quibim, S.L.

来自L-R：Quibim首席运营官Alberto Valiente，首席执行官Ángel Alberich Bayarri，财务与商业情报副总裁Javier Sáez。照片由Quibim，S.L。

As the saying goes, a picture is worth 1,000 words. But when it comes to medical imaging, sometimes those pictures just don’t say enough. Startup Quibim uses artificial intelligence to glean more insights from medical images and it has raised $50 million to continue commercializing its technology and to ramp up R&D that could broaden its offerings..

俗话说，一幅画抵得上1000个字。但当谈到医学成像时，有时这些图片还不够。初创公司Quibim利用人工智能从医学图像中收集更多见解，并筹集了5000万美元，继续将其技术商业化，并加大研发力度，以扩大其产品范围。。

“The main goal for the company is we would like to lead the category of imaging-based personalized medicine,” founder and CEO Ángel Alberich-Bayarri said.

创始人兼首席执行官安格尔·阿尔贝里希·巴亚里说：“公司的主要目标是，我们希望领导基于成像的个性化医疗领域。”。

The Quibim technology stems from Alberich-Bayarri’s experience as a biomedical engineer. He spent the early part of his career researching the use of imaging as a way to measure things. All of these images can have variations, he said. For each new patient, the algorithms he developed needed fine tuning.

Quibim技术源于Alberich Bayarri作为生物医学工程师的经验。在职业生涯的早期，他一直在研究如何使用成像来衡量事物。他说，所有这些图像都可能有变化。对于每个新患者，他开发的算法都需要微调。

Artificial intelligence was not part of the picture..

人工智能不在其中。。

presented by

提交人

Health IT

健康IT

Transforming Patient Care: The Role of AI-Powered Assistants

改变病人护理：人工智能辅助人员的作用

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.

人工智能（AI）的进步正在从各个方面重塑患者护理，从促进更快的出院到策划治疗计划并建议改变生活方式。

By IT Medical

通过IT Medical

The technology of Valencia, Spain-based Quibim creates what Alberich-Bayarri describes as image quality harmonization. By applying AI, the analysis can focus on biological changes rather than the confounding factors. Automation of this analysis means there is no longer any need for fine tuning, he said.

总部位于西班牙巴伦西亚的Quibim的技术创造了Alberich Bayarri所描述的图像质量协调。通过应用人工智能，分析可以关注生物学变化，而不是混杂因素。他说，这种分析的自动化意味着不再需要微调。

Furthermore, the technology automatically characterizes organs and tissues, identifying biomarkers indicative of disease..

此外，该技术自动表征器官和组织，识别指示疾病的生物标志物。。

“We were inspired by the fact that we can extract biomarkers from a blood sample,” Alberich-Bayarri said. “Why can’t we treat imaging data as a sample?”

Alberich Bayarri说：“我们从血液样本中提取生物标志物的事实启发了我们。”。“为什么我们不能将成像数据视为样本？”

The Quibim technology has received clearances from U.S. and European regulators as a medical device. At hospitals, clinicians can use the technology to guide disease detection and inform treatment decisions. So far, the company has regulatory clearances for applications of its technology to images of the prostate, the brain, and the liver.

Quibim技术作为一种医疗设备已获得美国和欧洲监管机构的许可。在医院，临床医生可以使用该技术来指导疾病检测并为治疗决策提供信息。到目前为止，该公司已获得监管许可，可以将其技术应用于前列腺、大脑和肝脏的图像。

Quibim also has a platform technology that analyzes multi-omics data from clinical trials and real-world studies. Alberich-Bayarri said pharma companies can use this capability to identify likely responders to a drug, which guides clinical trial enrollment..

Quibim还有一个平台技术，可以分析来自临床试验和现实世界研究的多组学数据。Alberich Bayarri说，制药公司可以利用这种能力来识别药物的可能反应者，从而指导临床试验的注册。。

Hospitals pay a subscription fee based on the size of the institution and the number of exams performed. Hospital customers include Mass General Brigham. As Quibim expands its U.S. footprint, Alberich-Bayarri said the company is also working to secure payer reimbursement. Payment from Quibim’s agreements with biopharmaceutical companies comes in the form of milestone payments.

医院根据机构规模和考试次数支付订阅费。医院客户包括马萨诸塞州的布莱根将军。随着Quibim扩大其在美国的业务范围，Alberich Bayarri表示，该公司也在努力确保付款人报销。Quibim与生物制药公司的协议以里程碑付款的形式支付。

In medical devices, Quibim has a collaboration with Philips, which integrates the startup’s AI models into its MRI scanners. Alberich-Bayarri said this is not an exclusive partnership and his company is looking to strike similar deals with other original equipment manufacturers..

在医疗设备方面，Quibim与飞利浦合作，飞利浦将初创公司的人工智能模型集成到其MRI扫描仪中。阿尔贝里希·巴亚里（AlberichBayarri）表示，这不是独家合作关系，他的公司正寻求与其他原始设备制造商达成类似协议。。

Sponsored Post

The Funding Model for Cancer Innovation is Broken — We Can Fix It

癌症创新的资助模式被打破了-我们可以修复它

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

缩小癌症健康公平差距需要通过新的资助方法实现医学突破。

By Eve McDavid - CEO of Mission-Driven Tech

作者Eve McDavid，任务驱动技术公司首席执行官

Quibim initially sought FDA clearance for the company’s entire platform. The regulator told Alberich-Bayarri he needed to break out regulatory submissions by indication. But Alberich-Bayarri still envisions a broader use of the company’s imaging capabilities. Right now, imaging data are fragmented and it’s rare to have a full-body MRI, Alberich-Bayarri said.

Quibim最初寻求FDA批准该公司的整个平台。监管机构告诉阿尔贝里希·巴亚里（AlberichBayarri），他需要通过指示打破监管提交的文件。但阿尔贝里希·巴亚里（AlberichBayarri）仍设想更广泛地使用该公司的成像功能。Alberich Bayarri说，目前，成像数据零散，很少进行全身MRI检查。

The company is building digital twins of organs, models that can be used for health monitoring. As the volume of imaging data grows, full-body imaging and AI models trained to analyze these images could be used to detect subtle tissue changes in the body, Alberich-Bayarri said. In this manner, imaging could be used at the beginning of a diagnosis rather than after symptoms show.

该公司正在构建器官的数字双胞胎，这些模型可用于健康监测。Alberich Bayarri说，随着成像数据量的增长，全身成像和经过训练分析这些图像的人工智能模型可用于检测体内细微的组织变化。通过这种方式，成像可以在诊断开始时使用，而不是在症状出现后使用。

The key is to be able to analyze the body as a whole..

关键是能够整体分析身体。。

“Diseases are not usually organ breakdowns, they are breakdowns of several things,” Alberich-Bayarri said. “In the future, I see imaging in prevention, when we are healthy in primary care, even when you don’t have symptoms.”

Alberich Bayarri说：“疾病通常不是器官衰竭，它们是多种事物的衰竭。”。“将来，当我们在初级保健中健康时，即使你没有症状，我也会在预防中看到成像。”

The merging of AI and personalized medicine is creating a new category of company based on drawing disease insights from medical images. One competitor to Quibim is Onc.AI, a digital health company focused on analyzing images to gain insights into tumor biology. Two years ago, the Bay Area-based startup .

人工智能和个性化医疗的融合正在创建一个新的公司类别，该类别基于从医学图像中提取疾病见解。。AI是一家数字健康公司，专注于分析图像以深入了解肿瘤生物学。两年前，这家位于湾区的初创公司。

raised $25 million

筹集2500万美元

in Series A financing.

在A系列融资中。

Quibim raised $8 million in seed financing in 2020, just prior to seeking its first FDA clearance for prostate imaging. The Series A financing announced Tuesday was led by Asabys and Buenavista Equity Partners. The latest financing added UI Investissements and GoHub Ventures as new investors. Other participants include earlier investors Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures and Leadwind, as well as individual investors such as Tony Fadell, principal at Build Collective, and Jonathan Milner, the founder of Abcam..

Quibim在2020年筹集了800万美元的种子资金，就在寻求FDA首次批准前列腺成像之前。周二宣布的A轮融资由Asabys和Buenavista Equity Partners牵头。最新融资增加了UI Investissements和GoHub Ventures作为新投资者。其他参与者包括早期投资者Amadeus Capital Partners、APEX Ventures、Partech、Adara Ventures和Leadwind，以及个人投资者，如Build Collective负责人托尼·法德尔和Abcam创始人乔纳森·米尔纳。。

Most of Quibim’s 89 employees are based in Europe. With the new capital, Alberich-Bayarri said his company will expand its U.S. presence, which is based in New York. The cash will also support the buildout of its sales team to continue striking deals with biopharma and medical device companies.

Quibim的89名员工大部分都在欧洲。阿尔贝里希·巴亚里（AlberichBayarri）表示，有了新资本，他的公司将扩大总部位于纽约的美国业务。这笔现金还将支持其销售团队的建设，以继续与生物制药和医疗器械公司达成协议。

Photo by Quibim, S.L.

照片由Quibim，S.L。

Topics

主题

artificial intelligence

人工智能

biopharma nl

生物制药 nl

medical imaging

医学影像学

medical technology